Drugs in development for the treatment of chronic hepatitis B

被引：4
作者：
Simone I. Strasser
机构：
[1] AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Missenden Rd.
来源：
Current Hepatitis Reports | 2012年 / 11卷 / 2期
关键词：
Bay; 41-4109; Clevudine; Emtricitabine; Entecavir; GS; 9620; Hepatitis B; Interferon; Myrcludex-B; Nitazoxanide; Novel therapies; Prodrug; REP; 9; AC; Tenofovir;
D O I：
10.1007/s11901-012-0131-9
中图分类号：
学科分类号：
摘要：
Currently available therapies for patients with chronic hepatitis B are safe, well tolerated, and highly effective in achieving improved outcomes reflecting potent viral suppression with low rates of antiviral resistance. For the majority of patients however, long-term treatment is necessary with significant cost implications and potential for complications. Current oral antiviral therapies are directed only at a single component of the hepatitis B lifecycle, while interferon therapy is effective only in a minority of patients. Efforts are underway to develop agents directed at novel targets derived from mechanisms of cellular entry, viral replication, or viral assembly leading to preclinical and clinical trials with impressive preliminary results. Additional development of agents directed at the host immune response offers the possibility of combination therapies with independent mechanisms of action that may pave the way for regimens of finite duration with long-lasting control of chronic hepatitis B infection. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：111 / 118
页数：7
相关论文
共 58 条
[1]  
Lok A.S., McMahon B.J., Chronic hepatitis B: Update 2009, Hepatology, 50, pp. 661-662, (2009)
[2]  
Clinical practice guidelines: Management of chronic hepatitis B, J Hepatol, 50, pp. 227-242, (2009)
[3]  
Liaw Y.F., Leung N., Kao J.H., Et al., Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update, Hepatol Int, 2, pp. 263-283, (2008)
[4]  
Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M., Control of cccDNA function in hepatitis B virus infection, J Hepatol, 51, pp. 581-592, (2009)
[5]  
Snow-Lampart A., Chappell B., Curtis M., Et al., No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus, Hepatology, 53, pp. 763-773, (2011)
[6]  
Moucari R., MacKiewicz V., Lada O., Et al., Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients, Hepatology, 49, pp. 1151-1157, (2009)
[7]  
Thomas H., Foster G., Platis D., Mechanisms of action of interferon and nucleoside analogues, J Hepatol, 39, (2003)
[8]  
Chang C.M., Jeng K.S., Hu C.P., Et al., Production of hepatitis B virus in vitro by transient expression of cloned HBV DNA in a hepatoma cell line, EMBO J, 6, pp. 675-680, (1987)
[9]  
Lutgehetmann M., Mancke L.V., Volz T., Et al., Human chimeric uPA mouse model to study hepatitis B and D virus interactions and preclinical drug evaluation, Hepatology, 55, pp. 685-694, (2012)
[10]  
Zlotnick A., Lee A., Bourne C.R., Johnson J.M., Domanico P.L., Stray S.J., In vitro screening for molecules that affect virus capsid assembly and other protein association reactions, Nat Protoc, 2, pp. 490-498, (2007)
123456